06
Jan

Gilead Sciences has shouldered its way into one of the industry’s hottest fields, agreeing to pay as much as $470 million to get its hands on potential treatments for nonalcoholic steatohepatitis (NASH).

…read more

Source: Gilead buys its way into the blockbuster NASH race with $470M deal

    

0 No comments